- Published on
Medicine – Acute Lymphoblastic Leukaemia (ALL)
Acute lymphoblastic leukaemia (ALL), also called acute lymphocytic leukaemia, is an aggressive haematological malignancy characterised by the uncontrolled proliferation of immature lymphoid precursor cells (lymphoblasts) in the bone marrow, peripheral blood and sometimes extramedullary tissues.
ALL is the most common childhood cancer, although it can also occur in adults.
The accumulation of lymphoblasts suppresses normal haematopoiesis, causing anaemia, neutropenia and thrombocytopenia.
ALL commonly presents in children with fever, pallor, bruising, infections, bone pain and hepatosplenomegaly. The diagnosis is established using bone marrow examination, immunophenotyping and genetic studies.
1. Epidemiology
- ALL predominantly affects children.
- Peak incidence occurs between 2 and 5 years of age.
- It is the most common acute leukaemia in children.
- Most childhood cases arise from B-cell precursors.
- T-cell ALL is less common and may present with a mediastinal mass.
- ALL also affects adults, particularly older adults, in whom outcomes are generally less favourable.
2. Pathophysiology
ALL arises from genetic abnormalities affecting immature B-cell or T-cell precursors.
These abnormalities cause uncontrolled lymphoblast proliferation and impaired differentiation.
Pathophysiology Flowchart
3. Classification
ALL is broadly classified into two major immunophenotypic groups.
| Type | Characteristics |
|---|---|
| B-ALL | Most common type in children; arises from immature B-cell precursors. |
| T-ALL | Arises from immature T-cell precursors; may cause mediastinal enlargement. |
Modern classification also incorporates genetic abnormalities, which influence prognosis and treatment.
4. Clinical Features
ALL commonly presents with bone marrow failure and infiltration of lymphoid or extramedullary tissues.
A. Fever
Fever is a common presenting feature and may occur due to infection or the underlying malignancy itself.
Infection must always be considered, particularly when neutropenia is present.
B. Anaemia
Anaemia results from suppression of normal red blood cell production.
Clinical features include:
- Pallor.
- Fatigue and lethargy.
- Dyspnoea.
- Dizziness.
- Reduced exercise tolerance.
C. Bleeding
Thrombocytopenia causes an increased bleeding tendency.
Manifestations include:
- Petechiae.
- Purpura.
- Epistaxis.
- Gum bleeding.
- Easy bruising.
D. Infection
Neutropenia and impaired immune function increase susceptibility to infections.
E. Hepatosplenomegaly and Lymphadenopathy
Leukaemic infiltration may cause:
- Hepatomegaly.
- Splenomegaly.
- Generalised lymphadenopathy.
F. Bone and Joint Pain
Bone pain is an important presenting feature, particularly in children.
It results from expansion and infiltration of the bone marrow.
Children may present with limping, refusal to walk or symptoms resembling musculoskeletal disease.
G. Central Nervous System (CNS) Involvement
ALL can infiltrate the meninges and central nervous system.
Possible manifestations include:
- Headache.
- Vomiting.
- Cranial nerve palsies.
- Diplopia.
- Seizures.
- Altered consciousness.
CNS involvement may occur even when neurological symptoms are absent, making CNS-directed treatment an essential component of ALL therapy.
H. Testicular Involvement
Testicular infiltration may occur, particularly in boys, and can present as painless testicular enlargement.
I. Mediastinal Mass
T-ALL may produce a large anterior mediastinal mass.
This may cause:
- Cough.
- Dyspnoea.
- Stridor.
- Superior vena cava obstruction.
5. Peripheral Blood Film
The peripheral blood film may demonstrate circulating lymphoblasts.
Lymphoblasts generally demonstrate:
- High nuclear-to-cytoplasmic ratio.
- Fine chromatin.
- Variable nucleoli.
- Relatively scant cytoplasm.
Unlike AML, Auer rods are absent in ALL.
Lymphoblast Schematic
Simplified educational illustration; not an actual blood film.
6. Investigations and Diagnosis
A. Full Blood Count
Possible findings include:
- Anaemia.
- Thrombocytopenia.
- Neutropenia.
- Elevated, normal or reduced total white cell count.
- Circulating lymphoblasts.
B. Peripheral Blood Film
May reveal lymphoblasts, although circulating blasts are not present in every patient.
C. Bone Marrow Examination
Bone marrow aspiration and biopsy are central to diagnosis.
ALL is generally associated with at least 20% lymphoblasts in the bone marrow, although diagnostic criteria and distinctions from lymphoblastic lymphoma depend on classification and clinical context.
D. Immunophenotyping
Flow cytometry distinguishes B-ALL from T-ALL and helps exclude AML.
| Marker | Association |
|---|---|
| TdT | Immature lymphoid precursors |
| CD19 | B-cell lineage |
| CD10 | Commonly expressed in B-ALL |
| CD22 / cytoplasmic CD79a | B-cell lineage |
| Cytoplasmic or surface CD3 | T-cell lineage |
| CD7 | Common T-cell marker |
| MPO | Usually negative in ALL |
E. Cytogenetic and Molecular Testing
Genetic abnormalities influence prognosis and guide treatment.
| Abnormality | Significance |
|---|---|
| ETV6::RUNX1, t(12;21) | Often favourable prognosis in childhood B-ALL |
| High hyperdiploidy | Generally favourable in childhood B-ALL |
| BCR::ABL1, t(9;22) | Philadelphia chromosome-positive ALL; requires targeted treatment |
| KMT2A rearrangement | Important high-risk association, particularly in infants |
| Hypodiploidy | Generally adverse-risk disease |
| BCR::ABL1-like ALL | Molecularly defined subgroup with variable actionable alterations |
F. Biochemical Investigations
- LDH may be elevated due to rapid cellular turnover.
- Uric acid may be elevated.
- Electrolyte abnormalities may occur.
- Renal function should be assessed.
- Liver function is evaluated before treatment.
G. Coagulation Profile
Coagulation abnormalities may occur.
DIC is not a defining or consistently present feature of ALL. It is particularly associated with acute promyelocytic leukaemia, a subtype of AML.
The historical figure of DIC in approximately 10% of ALL cases should not be treated as a universal diagnostic characteristic.
H. Lumbar Puncture
Cerebrospinal fluid examination is used to assess CNS involvement when clinically appropriate and safe, as part of specialist diagnostic and treatment protocols.
Diagnostic Flowchart
7. Treatment
ALL requires prolonged, multi-phase systemic therapy with CNS-directed treatment.
A. Induction Therapy
The aim is to achieve remission by eliminating most leukaemic cells.
Common drug classes include:
- Corticosteroids.
- Vincristine.
- Asparaginase.
- Anthracyclines in selected regimens.
B. Consolidation / Intensification
Further chemotherapy aims to eliminate residual leukaemic cells and reduce relapse risk.
C. CNS-Directed Therapy
CNS prophylaxis is essential because the CNS can act as a sanctuary site for leukaemic cells.
Treatment commonly includes intrathecal chemotherapy, such as methotrexate, with systemic CNS-active therapy.
Cranial radiotherapy is now reserved for selected circumstances rather than used routinely in most modern paediatric protocols.
D. Maintenance Therapy
Maintenance therapy is usually prolonged and commonly includes oral mercaptopurine and methotrexate-based treatment.
E. Targeted Therapy
Philadelphia chromosome-positive ALL requires a BCR::ABL1 tyrosine kinase inhibitor, combined with an appropriate systemic treatment regimen.
F. Immunotherapy
Selected patients may receive:
- Blinatumomab: A CD19-directed bispecific T-cell engager.
- Inotuzumab ozogamicin: A CD22-directed antibody–drug conjugate.
- CD19-directed CAR T-cell therapy: For eligible relapsed or refractory B-ALL.
G. Stem Cell Transplantation
Allogeneic haematopoietic stem cell transplantation may be considered for selected high-risk, persistent or relapsed disease.
H. Supportive Care
- Blood product transfusions.
- Infection prevention and treatment.
- Tumour lysis syndrome prevention.
- Nutritional and psychosocial support.
- Monitoring for treatment-related complications.
Treatment Flowchart
Simplified treatment sequence. Actual protocols include overlapping phases and additional therapy according to risk and response.
8. Prognosis
ALL prognosis depends on:
- Age.
- Immunophenotype.
- Genetic abnormalities.
- Treatment response.
- Measurable residual disease (MRD).
Children generally have better outcomes than adults.
With contemporary risk-adapted treatment, long-term survival exceeds 85–90% in many paediatric treatment programmes, although results vary by subtype and healthcare setting.
Adult ALL outcomes are more variable, and high-risk genetic abnormalities or persistent MRD may predict a greater risk of relapse.
9. ALL vs AML
| Feature | ALL | AML |
|---|---|---|
| Cell lineage | Lymphoid precursors | Myeloid precursors |
| Typical population | Predominantly children | Predominantly adults |
| Blood film | Lymphoblasts | Myeloblasts |
| Auer rods | Absent | May be present |
| TdT | Commonly positive | Usually negative |
| MPO | Usually negative | Often positive |
| CNS involvement | Important sanctuary site | Less common at presentation |
| Mediastinal mass | Particularly T-ALL | Less characteristic |
| Gingival infiltration | Less characteristic | Particularly monocytic AML |
| Treatment | Multi-phase chemotherapy, CNS prophylaxis, targeted/immunotherapy | Chemotherapy, targeted therapy ± transplantation |
10. High-Yield Examination Summary
| Feature | Key Point |
|---|---|
| Definition | Malignant proliferation of lymphoblasts |
| Typical population | Children |
| Peak age | 2–5 years |
| Main presentation | Bone marrow failure |
| Clinical features | Fever, pallor, bleeding, infection |
| Other findings | Bone pain, lymphadenopathy, hepatosplenomegaly |
| CNS involvement | Important clinical and treatment consideration |
| Blood film | Circulating lymphoblasts may be present |
| Auer rods | Absent |
| Immunophenotype | TdT+, with B- or T-lineage markers |
| Diagnosis | Bone marrow, flow cytometry and genetic testing |
| LDH | Often elevated |
| DIC | Not a characteristic defining feature |
| Treatment | Multi-phase chemotherapy and CNS-directed therapy |
| Targeted therapy | TKIs for BCR::ABL1-positive ALL |
| Prognosis | Often excellent in children; more variable in adults |
11. Key Examination Pearls
- ALL is the most common childhood cancer.
- The peak incidence occurs between 2 and 5 years of age.
- Bone marrow failure causes anaemia, infection and bleeding.
- Bone and joint pain may be prominent in children.
- Hepatosplenomegaly and lymphadenopathy may occur.
- T-ALL may present with an anterior mediastinal mass.
- CNS involvement is clinically important, even when asymptomatic.
- Auer rods are absent in ALL.
- TdT is a characteristic marker of lymphoblast immaturity.
- Bone marrow examination, immunophenotyping and molecular studies establish the diagnosis.
- CNS prophylaxis is an essential component of treatment.
- MRD is a major prognostic and treatment-guiding marker.
- Modern paediatric ALL outcomes are substantially better than historical cure-rate estimates.
A child presenting with fever, pallor, bruising, bone pain and hepatosplenomegaly, together with circulating lymphoblasts, should raise suspicion of acute lymphoblastic leukaemia.
Suspected ALL requires prompt specialist assessment. Fever with neutropenia, significant bleeding, respiratory compromise from a mediastinal mass or neurological deterioration requires emergency management.
Kembara Xtra – Medicine Revision Notes